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ABSTRACT 
 
 
  
 The purpose of this project is to bring attention to the impact of stem cells and their 
applications on society.  Despite what many people believe, there are multiple types of stem 
cells. These stem cells can be utilized for many different applications including regenerative 
medicine.  A topic as controversial as stem cells draws strong ethical concerns, which prompt the 
creation of legislations to dictate the boundaries of this new technology. 
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PROJECT OBJECTIVES 
 
 The purpose of this project is to demonstrate the impact that various stem cell 
technologies have on society.  Chapter-1 will focus on the different types of stem cells and their 
sources, including embryonic and adult stem cells, and describe new stem cell technologies such 
as iPS cells and parthenotes.  Chapter-2 will spotlight stem cell applications for the treatment of 
debilitating human diseases, such as SCID (severe combined immunodeficiency disease), 
Parkinson‟s disease, and diabetes.  Stem cell therapies for spinal cord injuries and cardiac 
damage are also included in Chapter-2.  Chapter-3 will discuss the ethical dilemmas associated 
with stem cell research, particularly for embryonic stem cell research.  Different religious 
perspectives regarding stem cell research will also be provided in Chapter-3.  Chapter-4, will 
focus on stem cell legalities, including the Bush administration‟s stem cell policy, the Obama 
administration‟s stem cell policy, and state and international stem cell laws.  Finally, as a 
conclusion to this project, the authors include their perspective on stem cell research and how it 
has impacted society. 
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Chapter 1 – Stem Cells: Types and Sources 
Catherine Campbell 
 
 Stem cells are the foundation for every cell, organ, and tissue in the human body (ISSCR, 
2009).  In general, stem cells are undifferentiated cells that have not yet completely specialized 
into a specific cell type (ISSCR, 2009).  These special cells are capable of long-term self 
renewal, meaning that they can proliferate over extended periods of time, and they eventually 
give rise to more stem cells (ISSCR, 2009).  Stem cells are capable of proliferating indefinitely, 
and under the proper conditions, will give rise to various cell types found in the body 
(Kirschstein and Skirboll, 2001).  An important characteristic of stem cells is that only one of the 
daughter cells will go on to differentiate, while the other daughter cell remains undifferentiated 
to maintain the stem cell reservoir (Kiessling and Anderson, 2003). 
 Unlike popular conceptions that use the term “stem cells” as if there is only one type, 
numerous kinds of stem cells exist, all unified by a few unique properties that make them stem 
cells.  All stem cells have the ability to divide and replenish themselves for extended periods of 
time, they are all unspecialized cells, and they are capable of yielding specialized cell types 
within the human body (NIH, 2005).  Stem cells are able to proliferate numerous times 
throughout their life cycle.  In fact, a small population of stem cells can, over a period of many 
months within a laboratory setting, eventually yield millions of stem cells (NIH, 2005).  If the 
resulting stem cell line is able to remain undifferentiated, then the cells are considered to have 
long term self-renewal abilities (NIH, 2005).  Stem cells are unspecialized, or undifferentiated, 
meaning that these cells do not contain tissue-specific structures.  These cells are unable to 
perform specialized functions, and therefore are unspecialized (NIH, 2005).  However, these 
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unspecialized cells can proliferate and produce cells that will eventually become specialized 
cells, such as cardiac muscle cells and nerve cells (NIH, 2005).   
 Stem cells can produce specialized cells in a process known as differentiation.  During 
the differentiation process, the cell undergoes a series of steps which allows it to become 
increasingly specialized.  Internal signals that initiate and allow the progression of differentiation 
are controlled by the cell‟s genes, which encode proteins and other molecules responsible for 
cellular structures and functions (NIH, 2005).  External signals are also required for the cell to 
fully initiate the differentiation pathway.  Such signals include chemicals released by local cells, 
cell-cell contact, and various molecules within the microenvironment (NIH, 2005).  Signal 
interactions during the process of differentiation allows epigenetic factors to accumulate in the 
cells‟ DNA, which function to restrict protein expression in the cell which can then be inherited 
by daughter cells through mitosis (NIH, 2005). 
 Because of the ability of stem cells to grow to large quantities and differentiate into 
various tissues, they are the basis of the new field of “regenerative medicine”.  The purpose of 
this chapter is to document the various types of stem cells and their sources, as a prelude to 
subsequent chapters on their uses, ethics, and legalities. 
 
Stem Cell Classifications 
Stem cells can be divided into three main categories:  embryonic stem (ES) cells, adult 
stem cells (ASCs), and induced pluripotent stem (iPS) cells.  ES cells denote any type of stem 
cell derived from an embryo.  Adult stem cells (ASCs), by definition, are stem cells isolated 
from adult tissues, but this category has also evolved to include any type of stem cell that is not 
produced from an embryo and not induced, thus this category also includes stem cells obtained 
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from fetal umbilical cord blood.   iPS cells are ES-like cells derived from adult fibroblast cells 
induced to de-differentiate using key developmental transcription factors. 
Stem cells can also be divided into types based on their potencies.  Totipotent cells 
(newly fertilized eggs through the 8 cell stage) can create any type of cell in the body including 
placenta.  Pluripotent cells (ES cells) can create any type of cell except placenta.  Multipotent 
cells can create several types of cells.  Unipotent cells (most types of adult stem cells) can create 
only one type of cell from their tissue of origin.  
 
Adult Stem Cells 
 Adult stem cells (ASCs) are tissue-specific cells present in various fetal and adult tissues 
that can only give rise to a limited number of cell types, depending on the type of tissues they 
reside, meaning they are unipotent or multipotent, but not pluripotent (ISSCR, 2009).  This 
indicates that they can become more than one cell type in the body, however, they are limited to 
the type of cell they can become.  Adult stem cells can proliferate for extended periods of time, 
give rise to mature and specialized cell types, and generate progenitor cell types before they 
achieve complete differentiation status (Kirschstein and Skirboll, 2001).  Progenitor cells, 
located throughout adult tissues, are partially differentiated cells that can divide and eventually 
produce differentiated cell types.  Adult stem cells are also capable of long term self-renewal for 
the lifetime of the organism, and are clonogenic and unilineal (Kirschstein and Skirboll, 2001).   
The term clonogenic indicates that these cells can generate identical copies of themselves.  
Unilineal denotes their tendency to differentiate into mature cells of the tissue in which they 
reside (Adult Stem Cells, 2006).  ASCs do not necessarily come from adult human beings, rather 
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the term „adult‟ refers to the status of the organ from which stem cells are isolated from, such as 
fetal and adult organs. 
Adult stem cells, or ASCs, are relatively rare in the human body.  In fact, it is still unclear 
exactly which tissues have ASCs, and a fierce debate sometimes occurs with new claims in the 
literature.  The major function of adult stem cells is to replace dead and injured cells with new 
cells that are able to function properly (Adult Stem Cells, 2006).  All of these characteristics 
allow ASCs to help maintain homeostasis in the body (Kirschstein and Skirboll, 2001). 
 Plasticity is a term used to describe the ability of adult stem cells to differentiate into a 
specialized cell type of a different tissue (Kirschstein and Skirboll, 2001).  This process is also 
termed trans-differentiation since it denotes a change into a different type of tissue.  Several 
approaches have been used to demonstrate the plasticity of adult stem cells.  ASCs can be 
obtained from a genetically engineered mouse expressing a specific molecular tag in all of its 
cells which allow these cells to be followed after injection into a host to show how these cells 
integrate into new tissues in their environment, survive in these new tissues, and function like 
mature, specialized cells of that type of tissue (Kirschstein and Skirboll, 2001). 
 
Hematopoietic Stem Cells 
 With 50 years of experience studying hematopoietic stem cells (HSCs) it is expected that 
no other type of stem cell is better researched and characterized.  These stem cells have the 
greatest self-renewal ability compared to any other cell type in an adult tissue (NIH, 2005).  
HSCs give rise to blood and immune cells, and are responsible for the constant renewal of blood 
(NIH, 2005).  HSCs can be isolated from blood, bone marrow, and umbilical cord blood, and can 
renew themselves and differentiate into a variety of specialized blood cells (NIH, 2005).  They 
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are capable of moving out of the bone marrow and into circulation blood and they also undergo 
apoptosis, or programmed cell death (NIH, 2005) which makes them useful to scientists and the 
medical field. 
 The most common and traditional source for HSCs is bone marrow, which has been used 
for over 40 years.  For this method, physicians puncture the donor‟s hipbone and draw out bone 
marrow cells using a syringe (NIH, 2005).  Unfortunately, only one out of 100,000 cells within 
the bone marrow sample will be a HSC (NIH, 2005).  A second source of HSCs is from 
peripheral blood, which physicians now prefer to harvest donor stem cells from for clinical HSC 
transplantations (NIH, 2005).  This source is less enriched for HSCs than bone marrow, so to 
overcome the small number of stem cells in peripheral blood, researchers inject the donor with 
cytokines to stimulate the release of HSCs out of the bone marrow into the peripheral blood in a 
larger density (NIH, 2005).  Of these collected mobilized cells, about 5 to 20% of them are true 
HSCs (NIH, 2005).  A third source of HSCs is umbilical cord blood.  During the 1980‟s and 
1990‟s, physicians found that blood obtained from human umbilical cords and the placenta is 
rich in HSCs (NIH, 2005).  To date, the HSCs isolated from each of these sources appears to be 
functionally identical, with maybe the exception of cord HSCs that appear to be more primitive 
and induce fewer graft rejections (Viacord, 2004).  Although HSCs can also be obtained from the 
fetal hematopoietic system, such cells are not used clinically, but only for research.  At about 7 
days into the life of a mouse embryo, the earliest level of hematopoietic activity can be detected 
(NIH, 2005).  As embryonic and fetal development progresses, hematopoietic activity increases 
until it reaches the bone marrow near the time of birth of the fetus (NIH, 2005).   All of these 
sources serve as valuable reservoirs of hematopoietic stem cells. 
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Adult Neural Stem Cells 
 Since most regions of the brain lack the capacity for self regeneration, neural cells are 
particularly vulnerable to irreversible damage and disease (Bjorklund and Lindvall, 2000).  
Neural stem cells (NSCs) do not have the ability to initiate tissue repair on their own in the adult 
brain (Levesque, 2005), but  these cells can be stimulated to proliferate and to repair damaged 
brain tissue when exposed to specific conditions that stimulate certain genes (Levesque, 2005).  
Some regions of the brain are capable of self repair since they contain such neural stem cells 
(Cassidy and Frisen, 2001).  NSCs are located in the brain‟s ventricle walls, which are 
cerebrospinal fluid filled cavities, but they are very difficult to isolate since they constitute only 1 
in 300 cells located in the ventricles (Cassidy and Frisen, 2001).  NSCs have the potential to 
produce more neural stem cells, or neurons and supporting glia (Cassidy and Frisen, 2001).  
These recently discovered cells have sparked hope that they can be used to treat 
neurodegenerative disorders (Cassidy and Frisen, 2001).  However, before NSCs can be used to 
their full potential, it is crucial to achieve a better understanding of their proliferation controls 
and differentiation pathways (Gage, 2000). 
 NSCs are formed from a unique portion of the embryo, which only produces precursor 
cells that will become the central nervous system (Levesque, 2005).  Researchers have been 
studying adult NSCs to determine better methods for isolating and characterizing them.  Once 
these cells are isolated, they can be propagated for several months in a laboratory without 
undergoing differentiation (Levesque, 2005).  Adult NSCs have the ability to self replicate and to 
eventually form all the cell types present in the adult central nervous system (Levesque, 2005).   
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 There are numerous sources of NSCs in the adult mammalian brain.  One source are 
ependymal cells (Johansson et al., 1999).  Ependymal cells give rise to a cell type which 
proliferates to produce neurons which migrate throughout the brain (Johansson et al., 1999).  It 
has been shown that these cells increase the production of migratory cells which differentiate 
into differentiated neuronal cells in response to tissue injury in the central nervous system 
(Johansson et al., 1999).  Another source for NSCs is the subventricular zone (SVZ) cells (Lois 
and Alvarez-Buylla, 1993).  These cells can proliferate spontaneously in the adult brain, and can 
differentiate directly into neurons and glia in vitro (Lois and Alvarez-Buylla, 1993).  Another 
source of NSCs is the periventricular region of the adult mammalian brain (Rietze et al., 2001).  
The periventricular region of the brain contains functional stem cells that have the ability to 
generate neural and non-neural differentiated cell types of the central nervous system (Rietze et 
al., 2001).  Another source of NSCs is the adult striatum (Reynolds and Weiss, 1992).  Although 
neurogenesis in the central nervous system is believed to end after the birth of the fetus, cells 
obtained from the striatum of an adult brain have been shown to proliferate in vitro (Reynolds 
and Weiss, 1992).  This finding provided substantial evidence that neural stem cells exist in the 
striatum of the adult brain, and have the capacity to proliferate and differentiate into neurons and 
astrocytes (Reynolds and Weiss, 1992).  In mice, neural stem cells can also be obtained from the 
lateral ventricles of the adult mouse central nervous system, and have been shown to participate 
in cell repopulation in the forebrain in vivo, and can expand in vitro when exposed to epidermal 
growth factors (Weiss et al., 1996).  The spinal cord and the ventricular neuroaxis of the adult 
central nervous system has also been shown to be a vital source of multipotent neural stem cell 
(Weiss et al., 1996).  
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Adult Cardiac Stem Cells 
 The heart, like the brain, is almost completely composed of terminally differentiated cells 
(Beltrami et al., 2003).  However, the heart should not be considered as a terminally 
differentiated organ since it contains cardiac stem cells that can mildly support tissue 
regeneration (Beltrami et al., 2003).  Adult cardiac stem cells are self-renewing, clonogenic, and 
multipotent, and have been shown to give rise to various cell types including myocytes, smooth 
muscle cells, and endothelial cells (Beltrami et al., 2003).  When these cardiac stem cells are 
injected into an ischemic heart, cardiac stem cells will differentiate and proliferate into 
myocardial tissue (Beltrami et al., 2003).  Also, recent research has shown that the heart contains 
stem cell reservoirs which allow the cardiac muscle tissue to produce new cells after damage, 
disease, and injury (Touchette, 2004).  In rats when cardiac stem cells are injected into damaged 
rat hearts, new cardiac cells are generated to reconstitute the damaged cardiac tissue (Touchette, 
2004).  The existence of these adult cardiac stem cells holds many opportunities for the medical 
advancement of myocardial repair and treatment. 
 
Adult Epithelial Stem Cells 
 Homeostasis of the adult epidermis, the outer layer of skin tissue, is maintained by two 
different populations of progenitor cells (Clayton et al., 2007).  These two populations include 
self renewing stem cells and their progeny, both which have the ability to differentiate into 
specialized epidermal cell types (Clayton et al., 2007).  Cutaneous epithelial stem cells are 
considered to be the main source for this type of epidermal tissue regeneration (Cotsarelis et al., 
1999).  Through research, it has been determined that these cells undergo both symmetric and 
asymmetric cell division at rates which maintain homeostasis of the epidermis (Clayton et al., 
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2007).  Such scientific findings suggest that adult epithelial stem cells play an important role in 
the maintenance of epidermal tissue, and might be used in the future for treating various skin 
diseases or burn patients. 
 
Mesenchymal Stem Cells 
 Mesenchymal stem cells (MSCs) are multipotent adult stem cells which can be derived 
primarily from adult bone marrow (Hellmann et al., 2006).  They are capable of differentiating 
into numerous cell types, such as osteogenic, adipogenic, and chondrogenic cells (Jackson et al., 
2007), and it has even been suggested that these cells can differentiate into cell types beyond the 
mesenchymal lineage (Jackson et al., 2007).  For example, MSCs can differentiate into neural 
cells in vivo and in vitro (Jackson et al., 2007).  It is this multipotency property of MSCs, 
coupled with their adult source with few ethical concerns, which makes them especially 
attractive to researchers seeking future applications in regenerative medicine. 
 The differentiation pathway of mesenchymal stem cells has been shown to be controlled 
by their contact and exposure to certain extracellular matrix (ECM) proteins (Plopper et al., 
2007).  By exposing these stem cells to specific ECM proteins, specific integrin-associated 
signaling pathways can be activated, resulting in a specific differentiation fate of mesenchymal 
stem cells into bone, cartilage, or adipose tissue cells (Plopper et al., 2007). 
 Mesenchymal stem cells are responsible for adult bone fracture repair and remodeling, 
and for bone formation in the embryo (Bruder et al., 1994).  Such cells proliferate for extended 
periods of time while a subpopulation of these cells will go on to differentiate into mesenchymal 
cell lineages.  Mesenchymal cell lineages include bone, cartilage, ligament, tendon, and muscle 
cells (Bruder et al., 1994).  The manner in which mesenchymal stem cells differentiate into each 
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cell lineage is dependent on the presence of certain nutrients, bioactive factors, and various 
environmental influences (Bruder et al., 1994).  It is believed that new methods of cell therapy 
can be derived from understanding the cellular and molecular mechanisms involved in 
osteogenic differentiation of mesenchymal stem cells (Bruder et al., 1994).   
 
Adult Intestinal Stem Cells 
 One of the most rapidly self-renewing tissue in the human body is the adult intestinal 
epithelium (Barker et al., 2007).  In a mouse model, it has been shown that the epithelial layer of 
the small intestine, which is responsible for a majority of nutrient absorption in the body, self 
renews once every three to five days (Barker et al., 2007).  In order to support such a rapid turn-
over rate, the intestinal epithelium contains numerous cell types, all which have differentiated 
from intestinal stem cells.   
 Until recently, intestinal stem cells have been difficult to identify due to a lack of markers 
and efficient stem cell assays (Barker et al., 2007).  But with the use of mouse chimeras and 
post-injury tissue regeneration research, intestinal stem cells can now be defined and 
characterized (Barker et al., 2007).  These self-renewing stem cells continuously proliferate into 
cells that will eventually differentiate into all intestinal cell lineages (Barker et al., 2007). 
 
Adult Eye Stem Cells 
 The epithelial layer of the cornea is constantly renewing itself once every seven to 
fourteen days in most mammals (Majo et al., 2008).  In pigs, the whole ocular surface, including 
the cornea, is rich in eye stem cells (Majo et al., 2008).  These eye stem cells are oligopotent and 
possess the ability to produce colonies of cells that comprise the cornea and conjunctiva (Majo et 
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al., 2008).  A majority of these stem cells are contained within the limbal region of the eye, and 
these cells are responsible for long term self-renewal of the cornea (Majo et al., 2008). 
 
Embryonic Stem Cells (ES cells) 
 ES cells are pluripotent cells derived from the inner cell mass of a mammalian blastocyst 
cultured in an in vitro fertilization (IVF) procedure for about 5 days.  The in vivo equivalent 
would be the embryo prior to its implantation in the uterine wall (Edwards, 2001).  The 
blastocyst is the resulting structure of a newly fertilized egg which has divided multiple times for 
about 5 days, and consists of a hollow sphere of about 150 cells made up of two cell types: the 
surrounding trophoblast and the inner cell mass (ISSCR, 2009).  The trophoblast is a group of 
cells which will eventually become the placenta, while the inner cell mass (constituting the ES 
cells) gives rise to the fetus.   
 ES cells are capable of long term self renewal, meaning that they can undergo indefinite 
symmetrical cell divisions without differentiating into a specialized cell type (Kirschstein and 
Skirboll, 2001).  ES cells exist only at the earliest stages of embryonic development, and are 
pluripotent, meaning they give rise to all cell types in the body except the placenta (ISSCR, 
2009).  They maintain a normal karyotype, meaning that they exhibit and maintain a stable, 
normal diploid complement of chromosomes which is important with respect to their potential 
clinical use (Emanuel, 2006).  ES cells are able to integrate into all fetal tissues in development 
and to colonize germ lines and produce gametes (Kirschstein and Skirboll, 2001).  They are also 
clonogenic, which means that a single ES cell can give rise to an entire colony of genetically 
identical cells, or clones, that all exhibit the same properties and characteristics as the original ES 
cell.  ES cells express a hallmark transcription factor Oct-4, which is responsible for either 
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activating dedifferentiation genes or inhibiting differentiation target genes, and for maintaining 
ES cells in their proliferative, unspecialized state (NIH, 2005).  They can be induced to 
proliferate and grow in culture, and to differentiate under the proper conditions.  A unique 
quality of ES cells is they lack the G1 checkpoint in their cell cycle (Kirschstein and Skirboll, 
2001).  ES cells spend a majority of their time in the S phase of the cell cycle, when DNA is 
replicated and synthesized in preparation for nuclear and cytoplasmic division during mitosis .  
Also, ES cells express high levels of active telomerase, which is a ribonucleoprotein enzyme that 
adds telomere repeats to the ends of chromosomes to maintain their length (Odorico et al., 2001).  
High telomerase activity is highly correlated with immortality in other human cell lines (Odorico 
et al., 2001), and likely helps ES cells maintain their long life spans.  ES cells also do not require 
external stimuli to initiate DNA replication, unlike most other types of cells found in the body 
(Kirschstein and Skirboll, 2001).  ES cells do not exhibit X inactivation since they are 
undifferentiated.  X inactivation is a process that occurs in every somatic female cell, in which 
one of the two X chromosomes is permanently inactivated in the female organism (Kirschstein 
and Skirboll, 2001).  All of these characteristics are particularly unique to ES cells. 
 ES cells can be differentiated into specialized cells via several mechanisms.  One of the 
most common approaches for directing differentiation in ES cells is to alter the growth 
conditions by adding specific growth factors to the culture medium.  The addition of growth 
factors triggers specific gene expression patterns to induce a specific differentiation pathway 
(Conrad et al., 2008).  Another method for inducing and directing differentiation is to change the 
chemical composition of the surface of the plate.  If the plate surface is changed to an adherent 
substrate, then the ES cells will be prevented from interacting and differentiating in culture.  
However, if the plate surface is altered to become a nonadherent substrate, then the ES cells will 
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be allowed to aggregate and will then differentiate (Kirschstein and Skirboll, 2001).  Another 
method for directing differentiation is to insert foreign genes into the ES cells via transfection, 
which will insert the new genes into the host genome, thus triggering a specific differentiation 
pathway (Kirschstein and Skirboll, 2001).  All of these mechanisms are commonly used to 
produce differentiated cells from ES cells in culture. 
 The most widely studied ES cell line originated from mouse ES cells (ISSCR, 2006).  
Mouse ES cells have taught researchers a great deal concerning how pluripotent cells grow and 
differentiate, and the processes involved in embryonic development (ISSCR, 2009).  Mouse ES 
cells have served as a significant research subject for analyzing gene function and human disease 
(ISSCR, 2009).  Human ES cells were first isolated in 1998, and have been proven to be more 
difficult to work with than mouse ES cells (ISSCR, 2009).  Although relatively little is known 
about human ES cells, scientific researchers are making substantial progress in learning about 
human development, modeling human disease, and developing methods that could potentially 
produce cell therapies to restore damaged tissues (ISSCR, 2006). 
 The derivation of human ES cells currently demands the destruction of the human 
embryo ex utero, or outside the uterus.  However, a recent study in mice has indicated that it 
could be possible to produce ES cells from only a single cell biopsy, which would not disrupt the 
developmental potential of the remaining embryo (Klimanskaya et al., 2006).  This ability to 
produce new stem cell lines without requiring the destruction of the human embryo would 
undoubtedly address the many ethical concerns associated with ES cell derivation.  To further 
test this idea, experiments were conducted to determine whether human ES cells could be 
obtained from a single blastomere (Klimanskaya et al., 2006).  Unused embryos from in vitro 
fertilizations (IVFs) were used to obtain individual blastomeres separated from the embryo.  ES 
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cell cultures were then allowed to overgrow and form embryoid bodies, which readily 
differentiated into the cells comprising all three germ layer (Klimanskaya et al., 2006).  Based on 
the results, single-blastomere-derived human ES cells could be directed to differentiate into 
specific cells of interest, in vitro, in this case endothelial cells (Klimanskaya et al., 2006).  Based 
on this conclusion, human ES cells can be obtained without destruction of the human embryo. 
 
Induced Pluripotent Stem Cells 
 Induced pluripotent stem (iPS) cells are stem cells created from reprogrammed adult cells 
(Cyranoski, 2007).  iPS cells are derived from specialized adult cells (usually skin fibroblasts) 
reprogrammed to an unspecialized state that is similar to that of an ES cell (ISSCR, 2009).   It is 
believed that iPS cells may be the equivalent of ES cells in their gene expression (Aoi et al., 
2008).  iPS cells are produced by inserting copies of transcription factor genes crucial to ES cell 
pluripotency, into specialized cells using viral vectors (ISSCR, 2009).  iPS cells also require a 
specific and correct culture media in order to prevent them from differentiating into specialized 
cell types (Cyranoski, 2007).  In the future, it is hoped that iPS cells can be used for patient 
specific cell therapies while not requiring the destruction of an embryo. 
 iPS cells can be generated from mouse and human fibroblast cells via retroviral 
transduction of four transcription factors (Aoi et al., 2008).  However, iPS cells can also be 
produced without the use of viral vectors.   
The first derivation of iPS cells was in mice in 2006 (Takahashi et al., 2006).  Shinya 
Yamanaka‟s lab reported that they had successfully reprogrammed mouse skin cells into an 
embryonic-like state by infecting them with a virus containing four transcription factors (Check 
and Baker, 2009).  These cells were then termed “iPS” cells, for induced pluripotent stem cells.  
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Later, Andreas Nagy inserted genes, which encoded Yamanaka‟s four transcription factors, into 
a DNA segment that also contained a jumping gene referred to as piggyBAC (Check and Baker, 
2009).  This DNA segment, or cassette, could then be inserted into the genome of mouse or 
human skin cells, which would reprogram them back to an embryonic-like state (Check and 
Baker, 2009).  A transposase would then be used to remove the cassette from the mouse or 
human cells (Check and Baker, 2009), which allowed researchers the ability to produce iPS cells 
without the use of viruses as vectors.  Subsequent experiments showed that removing the c-Myc 
gene from the coctail treatment eliminated the formation of cancer cells from the iPS colonies 
(Kim et al., 2008; Nakagawa et al., 2008), and eventually allowed only 2 transfection factor 
genes to be used.  Later experiments even showed iPS cells could be induced from mouse 
fibroblast cells with no transcription factor genes, when the cells were incubated with four 
polyarginine proteins (New Scientist, 2009).  In the future, so long as iPS cells show the same 
pluripotency as ES cells, they may completely replace their use in the clinic. 
 
Parthenotes 
 Due to the numerous ethical concerns associated with the isolation and use of human 
embryonic stem cells, alternative sources of pluripotent stem cells have been explored.  Through 
extensive research, it has been discovered that parthenotes may serve as an alternative and 
ethical source of pluripotent stem cells (Brevini and Gandolfi, 2007).  Parthenotes are entities 
created via artificial parthenogenesis, in which human oocytes are artificially activated by 
chemical treatments to produce pluripotent stem cells (Brevini and Gandolfi, 2007).  In the 
process of parthenogenesis, embryonic development can be initiated just from maternal oocytes 
in the absence of a male‟s sperm (Cibelli et al., 2002).  Although parthenogenesis is a process 
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commonly used frequently in less complex organisms, such as insects and sea urchins, mammals 
are unable to initiate a successful pregnancy via parthenogenesis (Cibelli et al., 2002).  In 
primates, parthenogenesis in monkey oocyte development in vitro can successfully generate 
blastocysts from which ES cell lines were derived (Cibelli et al., 2002).  These pluripotent stem 
cells can be maintained undifferentiated in vitro for extended periods of time (Cibelli et al., 
2002).  Although parthenogenetic mammalian blastocysts will not survive long enough to be 
implanted into the uterine wall, they do last long enough to be used as a pluripotent stem cell 
source (Marchant, 2006).  Due to these results, parthenotes may serve as a replacement for 
human embryonic stem cells for patient-specific cell based therapies since they avoid the need to 
create human embryos for use. 
 Recently, pluripotent stem cells from human parthenotes have been isolated by 
researchers at the University of Milan (Marchant, 2006).  Donated eggs were used to derive these 
stem cell lines (Marchant, 2006).  Based on extensive research, the human parthenogenetic ES 
cells appear to be the equivalent of normal ES cells, while bypassing the need to create human 
embryos (Westphal, 2003).  Although such stem cells are slightly more difficult to manage and 
store in vitro than normal human ES cells, researchers are hopeful that they will eventually 
replace the need for fertilized embryos (Marchant, 2006). 
 
Somatic Cell Nuclear Transfer (SCNT) 
 A major issue associated with allogenic tissue transplantation is graft rejection by the 
host, in which the patient‟s immune cells attack the transplanted tissue (Byrne et al., 2007).  This 
complication could be potentially bypassed completely with the help of SCNT created stem cells, 
which would contain the genetic information of the recipient patient (Byrne et al., 2007).   
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 Somatic cell nuclear transfer (SCNT) is a process in which embryonic stem cells can be 
made genetically identical to a patient (Byrne et al., 2007).  In this process, a nucleus from an 
adult skin fibroblast cell of the eventual recipient is injected into an enucleated egg.  The egg is 
cultured 5 days in vitro to the blastocyst stage from which ES cells are then obtained genetically 
identical to the donor of the nucleus.  The technique has been successful in mice, but has not yet 
been done in humans.  SCNT techniques have the ability to potentially treat and cure numerous 
debilitating diseases while avoiding graft rejection in patients (Byrne et al., 2007).  ES cell lines 
created via SCNT have been shown to express markers specific to stem cells, exhibit typical ES 
cell morphology, and are able to transcriptionally maintain an undifferentiated state and control 
differentiation into various cell types in vivo and in vitro, similar to normal embryonic stem cells 
(Byrne et al., 2007).  Based on this information, it is evident that SCNT techniques can alleviate 
the risk of tissue rejection associated with many transplants, thus allowing the development of 
more personalized treatments for patients. 
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CHAPTER-2:  STEM CELL APPLICATIONS 
Kristin Newell 
 
Stem cells have a tremendous potential for use in regenerative medicine, and have been 
used to repair various damaged tissues (such as the spinal cord) and organs (like the heart), repair 
congenital defects, and reverse or improve many debilitating diseases such as Parkinson‟s 
disease, SCID, and even diabetes.  These applications of the use of stem cells in regenerative 
medicine and their benefits to society will be the focus of this chapter, as a prelude to subsequent 
chapters on their ethics and legalities. 
 
Treatment of Severe Combined Immunodeficiency Disease (SCID) 
Severe combined immunodeficiency disease (SCID) is a disorder in which both the B 
cells and T cells of the immune system are defective.  This disease is also commonly called 
“bubble boy” disease because of the famous case of David Vetter who suffered from SCID. 
SCID is most commonly caused by a defect in the γc T-cell receptor, and less commonly (as in 
David‟s case) by a defect in adenosine deaminase (ADA).  Individuals with SCID lack 
essentially all immune function and usually die within their first year of life due to severe 
recurrent infections, which a properly functioning immune system would be able to take care of 
(MedicineNet, 2003).  It is estimated that 40-100 cases of SCID are diagnosed each year in the 
United States, but there is no way to tell how many undiagnosed infants die each year of SCID 
(National Human Genome Research Institute, 2009).  
Hematopoietic stem cells (HSCs) present in bone marrow or umbilical cord blood are 
among the best characterized of all stem cell types, and have been used the longest to treat 
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diseases.  HSCs have been used for over 50 years in attempts to treat various forms of cancer 
(Thomas et al., 1957), with the 40
th
 anniversary of the first clinical success occurring in 2009 
(Bortin et al., 1994).  With respect to SCID treatments, as is typical for most new treatments, 
experiments were initiated in animals, and then later extended to humans.  In 1992, researchers 
implanted human bone marrow pre-treated with mast cell growth factors into SCID mice, which 
resulted in a re-population of mouse bone marrow with human erythroid and myeloid 
progenitors, that gave rise to all cells of the blood and immune system (Lapidot et al, 1992).  The 
recipient SCID mice that received implants without growth factor pre-treatment did not generate 
erythroid and myeloid progenitors, and produced few human cells in the mouse bone marrow, 
and only granulocyte-macrophage progenitors (Lapidot et al, 1992).  Thus, growth factor 
treatments are important when priming the HSC transplants.  A subsequent study found that 
SCID mice treated with a cytokine mixture for four months then implanted with human bone 
marrow (or a human bone fragment) established human blood cell lineages, detectable up to a 
year after implantation (Heike et al, 1995).   
The animal model experiments for SCID treatments were first successfully applied to 
humans in 2000 (Cavazzana-Calvo et al., 2000).  HSCs corrected for the most common type of 
SCID (a mutation in the γc T-cell receptor) were used to treat two SCID infants.  Both infants 
showed complete establishment of an immune system, the ability to respond to vaccine 
treatments, and clinical improvements.  It is now estimated that treatment with HSCs could save 
up to 80% of people diagnosed with SCID (NCBI, 2009). 
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Treatment of Parkinson’s Disease 
Parkinson‟s disease (PD) occurs when nerve cells (neurons) in a part of the brain called 
the substantia nigra (which produces dopamine) either die off or are impaired in their production 
of dopamine.  Dopamine is an important neurotransmitter that is responsible for smooth muscle 
coordinated movements.  Symptoms occur when 80% or more of these dopamine-producing 
neurons die or are dysfunctional.  The common symptoms of  PD are shaking, rigidity, slowness 
of movement, and difficulty balancing. Other less common symptoms include muffled speech, 
stiff facial expressions, shuffled walking, small cramped writing, and depression.  In the United 
States, 1.5 million people have PD, with an additional 60,000 new cases diagnosed each year 
(National Parkinson Foundation, 2009).  PD usually occurs at over 65 years of age, but 15% of 
new cases diagnosed occur in individuals 50 years of age or younger (National Parkinson 
Foundation, 2009). 
There has been some success in treating Parkinson‟s disease using embryonic stem (ES) 
cells, as well as neural stem cells (NSCs) already present in the brain, in both PD animal models 
and in patients.  In 2000, injection of transforming growth factor alpha (TGFα) into rats (pre-
treated with 6-OHDA to kill dopamine neurons) showed migration of endogenous neural stem 
cells to the damaged areas of the brain, and neural stem cell division for several days (Fallon et 
al., 2000).  These rats showed fewer PD symptoms than non-TGFα-treated rats who received the 
6-OHDA.  It is unknown, however, whether the repairs were caused by the TGFα inducing 
endogenous stem cell division and proliferation, or some other effect of the TGFα on the brain 
(Regenerative Medicine, 2006, p 40). 
In 2004, human embryonic stem cells (hESCs) treated to become neural progenitors were 
transplanted into the striatum of Parkinsonian rats, which resulted in the in vivo generation of a 
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small quantity of dopaminergic neurons (Ben-Hur et al., 2004).  The generation of these 
dopaminergic neurons resulted a lessening of the PD symptoms, including substantial 
improvements in stepping, behavioral tests, and a partial increase in apomorphine-induced and 
D-amphetamine rotational behavior (Ben-Hur et al., 2004).  Another 2004 study involving the 
implantation of hESCs pre-treated to differentiate into neural cells, resulted in a reduction in the 
Parkinson‟s like symptoms in mice (Ryan, 2004).  A post-mortem investigation revealed the 
presence of dopamine-releasing cells generated from the transplanted hESC, and the hESC did 
not continue to proliferate to cause cancerous tumor formation within the 12 weeks the mice 
were monitored following the treatment (Ryan, 2004). 
In animals, scientists have also provided donor animals with genetically matched 
transplant tissue generated by somatic cell nuclear transfer (SCNT).  In this process, the nucleus 
from a skin fibroblast cell is injected into an enucleated egg.  The egg is grown for about 5 days 
to the blastocyst stage, from which ES cells are isolated genetically identical to the individual 
from which the skin cell was obtained.  This process is of considerable interest lately since it can 
eventually provide patients with ES treatments eliminating graft rejection. Scientists have had 
success generating dopamine neurons using this technique in mice and primates (Regenerative 
Medicine, 2006, p 40). 
Stem cells have not yet been used to treat patients with PD, but some studies have used 
transplants with embryonic tissue.  In one 2001 study, human embryonic dopamine neurons 
(derived from embryonic mesencephalic tissue) were transplanted into the putamen of the brain 
of individuals with severe Parkinson's disease.  Of the patients receiving the transplant, 
significant improvement occurred in patients younger than 60 compared to those receiving a 
mock surgery, but no significant improvement was seen in transplant patients over the age of 60.  
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The improvements were long lasting in a majority of the patients, however for 15% of the 
patients, after improvement within the first year following the transplant, dyskinesias (difficulty 
performing voluntary movements), and dystonia (involuntary muscle contraction) returned 
(Freed et al., 2001).  However, as we will learn in Chapter-3, treatments with embryonic tissues 
(as in the above experiment) are even more controversial than ES treatments since they involve 
isolating tissues from aborted fetuses.  With respect to stem cells and PD, human PD patients 
have not yet been treated with hESCs, so this application remains in the future. 
 
Treatment of Spinal Cord Injury 
Spinal cord injury results most frequently from trauma or disease.  The spinal cord is a 
bundle of nerves that goes through the middle of the spinal column (middle of the vertebra) 
carrying nerve signals from the brain to the rest of the body and back.  The spinal cord does not 
have to be severed to lose function; in fact, in most spinal cord injuries, the spinal cord is not 
severed at all (Spinal Cord Injury Resource Center, 2009).  Most spinal cord injuries result in the 
loss of sensation and movement (paralysis) below the injury site. Paralysis affecting the majority 
of the body, including the arms and legs, is called quadriplegia, and paralysis affecting the lower 
body is called paraplegia (Mayo Clinic, 2009).  In the United States, 40 of every million people 
have a spinal cord injury. This number does not include those people who die at the scene of the 
accident.  Each year in the U.S. there are 12,000 new cases of spinal cord injuries (Spinal Cord 
Injury Facts, 2009). 
In most spinal cord injuries, although the spinal cord is not completely severed, the 
remaining intact nerve axons become demyelinated due to the lack of the myelin oligo-
dendrocytes as a result of the injury (Regenerative Medicine, 2006, p 40).  In one 2000 animal 
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study, scientists coaxed the hESCs to differentiate into early stage oligodendrocytes (myelin 
producing cells) before transplantation into chemically demyelinated rats (Liu et al., 2000).  In 
rats that had undergone a partial injury to the spinal cord less than seven days previously, saw 
myelin growth around the damaged neurons, and showed an increase in walking capability. In 
rats who received the transplant 10 months after partial injury, no myelin growth was seen, likely 
due to the preventative effects of the formed scar tissue, regardless of the presence of mature 
oligodendrocytes at the site of injury. These rats, therefore, saw no increase in walking 
capabilities.   This study was repeated in 2005 where scientists found that hESC-derived cells, 
after implantation in rats, restored myelin to neurons within seven days of the initial injury and a 
restoration of motor function (UC Irvine, 2005).  In another animal study, mouse ESCs were 
treated to ensure differentiation into neurons, and then injected into the injured area of a rat's 
spine that had been severely bruised (Sheppa, 2000).  Injection within nine days of injury 
resulted in restoration of hind leg function, and the presence of new neurons, oligodendrocytes, 
and astrocytes.  Of the roughly 1 million injected mouse ES cells, most had died within 2 weeks, 
but enough remained to form the oligodendrocytes, astrocytes, and new neurons at the injury 
site.  The blunt trauma the rats suffered from is the same type of trauma to the spinal cord that 
most people with spinal cord injuries experience (Sheppa, 2000). 
In a 2006 study, differentiation of embryonic glial-restricted precursors (GRPs) into 
GRP-derived astrocytes and injection into a rat damaged spinal cord, promoted axon growth of 
damaged neurons, in some cases even beyond the injured area.  The treatment resulted in a 
realignment of the injured area, increased locomotion, suppression of scaring, and rescued axons 
cut from atrophy (Davies, 2006).   
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Stem cells have not yet been used to treat human spinal cord patients.  Some scientists 
believe that when such treatments are allowed, they will be administered during the recovery 
stage in which rods and ties are placed around the spinal column for stabilization (UC Irvine, 
2005).  But before this happens, scientists say more animal research must occur to insure patient 
safety (Regenerative Medicine, 2006, p 42). 
 
Treatment of Diabetes 
Diabetes occurs when insulin is improperly used or is not produced by the body. Insulin 
is responsible for the conversion of starches and sugars (glucose) into energy.  In the United 
States alone, 23.6 million people have diabetes, and 57 million people in the U.S. have pre-
diabetes, a condition in which a person‟s blood glucose level is higher than normal but not high 
enough to be considered diabetes.  There are various forms of the disease: Type 1, Type 2, and 
gestational diabetes.  In Type 1 diabetes the body does not produce insulin in response to high 
glucose levels. Type 2 diabetes, the most common form of the disease, is characterized by 
improper use of insulin by the body (insulin resistance), as well as lower than normal levels of 
insulin production.  Gestational diabetes is a condition in which, during pregnancy, a woman‟s 
body does not properly use insulin, and 5% – 10% of women with gestational diabetes are found 
to have Type 2 diabetes following their pregnancy (American Diabetes Association, 2009). 
 Stem cells have been shown in animal studies to differentiate into insulin producing cells 
that can be used to treat diabetes.  In mice, scientists have been able to develop pancreatic cells 
that secrete insulin in response to glucose, as well as other pancreatic endocrine hormones, by 
differentiating mouse ESC.  These cells when injected into  diabetic mice, even developed in a 
three dimensional structure, similar to that seen in vivo in pancreatic islets, which retained its 
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shape and rapidly became vascularized (Lumelsky et al., 2001).  Mouse ESCs have been shown 
to be capable of differentiating into insulin-producing cells and restoring normal glycemia in 
diabetic mice (Roche et al., 2003).  
In addition to ES cells, HSCs have also been used in animal studies to treat diabetes.  
Administration of mouse bone marrow-derived stem cells into the islets and ductile regions of 
the pancreas, in STZ poisoned mice (to mimic diabetes) resulted in the proliferation of pancreatic 
cells, insulin production, and lowered hyperglycemia (Hess et al., 2003). This application of 
bone marrow-derived stem cells has the potential for use in pancreatic β-cell regeneration. 
With respect to human ES experiments, one 2005 study showed that hESCs if treated 
correctly can, in vitro, differentiate into the pancreatic cells responsible for insulin production (β-
cells in the islets of Langerhans) (Assady et al., 2005). These β-cells proved to be functional 
insulin-producing cells, and although such cells have not yet been transplanted into humans, 
scientists hope they can be used to treat patients with type-1 diabetes (Assady et al., 2005). 
Scientists have also been able to direct hESCs to develop into endocrine (hormone secreting) 
cells capable of secreting insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin, in 
vitro, that mimic the development of the tissue during fetal development (D'Amour, 2006).  
 
Treatment of Cardiac Damage 
Congestive heart failure, a condition in which the heart does not pump enough blood out 
of the heart, occurs from damage such as a heart attack, or a pulmonary embolism.  It affects 
400,000 new people each year in the United States.  It is estimated that there are currently five 
million people in the United States with congestive heart failure (Optimal Heart Health, 2009). 
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Various types of cells have been used to treat heart damage.  These cells can be delivered to the 
damaged heart muscle in a few ways: intravenous injection, injection directly into the coronary 
artery, or injection directly into the ventricular wall (endomyocardial injection) (Regenerative 
Medicine, 2006, pg 58-59). 
Skeletal myoblasts (SMs) were the first “stem” cell type explored for cardiac repair due 
to their high proliferation rate, commitment to differentiate into muscle tissue, and resistance to 
ischemia.  SMs have been shown to repopulate scar tissue resulting in increased ventricular 
functioning in rat and human studies (Dowell et al., 2003).   However, these SM-derived 
cardiomyocytes have a contractile function separate from that of the native myocardium, and are 
unaffected by their electrical impulses (Leobon et al., 2003). Unfortunately early studies using 
SMs for cardiac muscle repair lead to sustained ventricular tachycardia, a potentially fatal heart 
arrhythmia, likely caused by the lack of an electrical interaction between the SM-derived cells 
and the regular myocardium of the heart (Menasche et al., 2003; Siminiak et al., 2004). 
In mice, injection of bone marrow-derived stem cells into the ventricular wall following 
an induced heart attack, resulted in 70 percent of the scar tissue being repopulated with new 
smooth muscle, cardiomyocytes, and vascular endothelial cells (Orlic et al., 2001).  However it 
has not yet been proven whether this repopulation was actually generated from the bone-marrow 
derived cells (Regenerative Medicine, 2006, p 60).  Mesenchymal stem cells (MSCs), found in 
bone marrow, differentiate into adipose tissue, muscle, bone, tendons, ligaments and fibroblasts. 
MSCs remain multipotent in vitro, can be frozen, have relatively little immunogenicity, and are 
easily extracted from autologous bone marrow. Injection of non-host MSCs into damaged heart 
tissue, in animal studies, has resulted in increased heart muscle function, and capillary formation, 
and elicited no immune response from the host(MacKenzie, Flake, 2002).  MSCs have the 
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benefit of having a low immunogenicity (ability to cause an immune response) and therefore 
have an advantage for use in human trials (Amado et al., 2005).  Endothelial progenitor cells 
(EPCs) are bone-marrow derived stem cells that give rise to the endothelium (inner lining of the 
heart) (Rosenstrauch et al., 2005), and home in on damaged vascular tissue to form new vascular 
tissue in response to a heart attack or ischemia (loss of blood flow) (Kocher et al., 2001).  Within 
48 hours after intravenous injection of EPCs (Kocher et al., 2001), the graft helped prevent left 
ventricular (LV) remodeling and myocyte apoptosis (programmed cell death) (Shuster et al., 
2004).  
Resident cardiac stem cells have been isolated in rat, mouse, and human specimens 
(Beltrami et al., 2003; Messina et al., 2004), which have the ability to repair damaged heart 
tissue and replace dead heart muscle cells (Boyle et al., 2006). However, few cardiac stem cells 
can be isolated from the heart, so these cells require proliferation ex vivo (outside the body) 
before being injected into the site of myocardial (heart muscle) damage. These cells have the 
ability to increase systolic function as well as develop into myocardium (Messina et al., 2005).  
Injection of umbilical cord blood (UBC) HSCs into a rat having a myocardial infarction 
resulted in the development of new blood vessels when injected intravenously (Ma et al., 2005), 
and an  increase in ventricular function when injected directly into the damaged tissue (Hirata et 
al., 2005).  Following intravenous injection of UCB HSCs, a DNA assay showed that the UCB 
stem cells had also migrated to the liver, spleen, and bone marrow of the host (Hirata et al., 
2005).  Autologous fibroblasts, obtained from adult rat peripheral blood has been shown to cause 
an increase in elasticity in scar tissue upon direct injection into the site of damage in a post 
infarction rat heart, although the heart showed no increase in function. Scientists believe that 
 35 
these cells may be beneficial to elderly patients who have decreased numbers of bone marrow 
stem cells or autologous skeletal myoblasts (Regenerative Medicine, 2006, p 62).  
Scientists discovered that a gene manipulation in differentiating murine (rat or mouse) 
ESCs results in an essentially pure culture of cardiomyocytes suitable for use in grafts.  These 
engrafted cells lasted longer than seven weeks (the longest time they were tested) (Klug et al., 
1996).  Undifferentiated rat ESCs used to treat infarcted rat hearts which differentiated into new 
functional cardiomyocytes occupying the damaged area with little scarring, normal ventricular 
architecture, and were capable of increased cardiac output. There was also no tumor formation, 
irregular electrical output, sudden cardiac death, or graft rejection (Terzic, 2004). 
With respect to human treatments, scientists have been able to create a differentiation 
system that can guide human ES cells in vivo to develop into cardiac tissue, which holds great 
potential for use in functional genomics, pharmacological testing, tissue engineering, cell 
therapy, and the study of early cardiac development.  Human ESCs cultured in suspension and 
treated for differentiation, developed into ESC-derived cardiomyocytes that shared structural and 
functional properties with early-stage cardiomyocytes (Kehat et al, 2001).  A 2006 study showed 
that patients with acute myocardial infarction showed lower death rates, increased left ventricular 
contractibility, and increased revascularization following bone marrow stem cell injection 
(Schächinger et al, 2006).  Some success has also been shown in a human stem cell clinical trial. 
A 16 year-old boy, accidentally shot in the heart with a nail gun, subsequently had a heart attack.  
Doctors administered a drug to increase the concentration of HSCs in his blood, harvested these 
stem cells and then injected them into the artery that supplies blood flow to the front of the heart 
(in his case which contained mostly dead cardiac tissue).  A week after the surgery, he was 
released from the hospital to finish recovering at home.  Doctors reported they had never seen a 
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recovery like his; following his surgery his cardiac function was significantly increased.  
However, being cautious, Doctors also say that these may be age independent results and the 
procedure may not obtain the similar results in older patients.  And it remains to be proven 
whether the HSC cell injection resulted in the improvement (Philipkoski, 2003). 
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Chapter 3 – Stem Cell Ethics 
Catherine Campbell 
 
Stem cell research is one of the most promising areas of medical research.  But for 
research to continue, scientists require stem cell lines, isolated either from adult stem cells 
(ASCs), or the more controversial embryonic stem (ES) cells.  Although there are few ethical 
issues associated with using adult stem cells, there are numerous dilemmas stemming from ES 
cell research.  Some people are opposed to stem cell research for secular and religious reasons, 
while others are in favor of stem cell research due to its potential for producing new medical 
treatments.   In a national Gallop Poll conducted in 2005, about 60% of people supported stem 
cell research and approximately 30% were opposed to it (ABC News, 2007).  Meanwhile, 73% 
of people polled were in favor of using discarded embryos for stem cell research for the 
development of potential medical cures, while only 19% were opposed to it (ABC News, 2007).  
It is evident that there is a clear split in opinions regarding stem cell research, a trend identified 
in almost every population around the world.  The purpose of this chapter is to investigate the 
ethics of stem cell research, both adult and embryonic, to introduce a discussion about whether 
we “should” work with stem cells, and to also provide a prelude for a subsequent chapter 
discussion on stem cell legalities. 
 
The Ethics of Adult and Embryonic Stem Cell Research 
Among the many areas of scientific study, few have as much potential for producing new 
medical treatments for debilitating disease as stem cells.  Some scientists have even gone as far 
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as to say that stem cell research may lead to some of the most prominent miracle cures of the 
twenty-first century (Elliot and Porowski, 2005).  While adult stem cell use has few ethical 
issues, ES cell research has produced many heated ethical debates (Elliot and Porowski, 2005).  
Given the fewer ethical issues associated with ASCs, one might simply argue that ES cell use 
should be abandoned, however  most scientists believe it is far too premature to abandon ES cells 
because (as discussed in Chapter-2) ASCs are difficult to isolate, difficult grow in culture, and 
most types have not proven as medically useful as ES cells. 
 The ES cell debate has its origins in the late 1960‟s with the advent of human in vitro 
fertilization (IVF) technology.  As IVF clinics made their debut, and more couples donated 
sperm and egg, debates ensued about what to do with the excess embryos after the couple had 
enough children.  Usually the excess IVF embryos were destroyed, which some called murder. 
The human ES cell debate began in 1998, when scientists in the United States first isolated ES 
cells from a human embryo (Thomson et al., 1998; Bhikkhu, 2007).  As discussed in Chapter-1, 
ES cells are usually isolated from the inner cell mass of IVF blastocyst embryos provided with 
donor consent from IVF clinics, so the same debates that began in the 1960‟s about embryo use 
still pertain to ES cell research.   
 With respect to embryo sources, relatively few people in the U.S. support the payment of 
egg donors for research purposes, so those in favor of ES cell research generally believe that it is 
more ethical to use embryos left over from fertility clinics instead of discarding them (Bhikkhu, 
2007).   In fact, the United States alone contains possibly hundreds or thousands of such IVF 
embryos (Bhikkhu, 2007), and Obama‟s recent stem cell legislations (discussed in Chapter-4) 
outlaw payment for this purpose. 
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 With respect to destruction of the embryo, the debate eventually centers on when life 
begins.  On this topic, ES cell research creates an ethical dilemma for many people in both the 
secular and religious sense.  Some believe life starts at the moment of conception, when an egg is 
fertilized by a sperm, while others consider life to begin later at the primitive streak, or even at 
birth (Derbyshire, 2001).  Since stem cell research can involve the destruction of human 
embryos, it is evident that the moral status of the human embryo is heavily debated.  Essentially, 
there are two categories of moral thinking when it comes to opposing ES cell research.  There is 
the belief that the human embryo is a person with rights, including the right to life, and thus the 
destruction of the embryo is murder (Derbyshire, 2001).  Then, there is the belief that the embryo 
is not yet a person, however, it possesses the potential to develop into a human being (Shannon, 
2006; Derbyshire, 2001).  According to the first type of moral thinking, the human embryo is 
symbolically valuable, and therefore must be protected from harm (Derbyshire, 2001).  Then, 
there is the supportive side of ES cell research.  Some in favor of ES cell research consider the 
embryo to be a mere collection of cells, and thus the embryo is no more alive or human than a 
tumor or a virus (Derbyshire, 2001).  And some major religions believe that life begins well after 
day-5 when the ES cells would be isolated (discussed below).   According to this second line of 
thought, the destruction of the human embryo is justified, considering that life begins later, and  
potential good for society may result from ES cells. 
Some U.S. citizens are opposed to ES cell research not only for religious reasons, but also 
because of ability of scientists to affect and manipulate human life (Bhikkhu, 2007).  They argue 
that society should strive to free others from debilitating disease using the most ethical means 
possible (i.e. ASCs not ES cells) (Bhikkhu, 2007).  On the other hand, others believe that it 
would be unethical not to try to save lives using ES cells.  They argue that potential for medical 
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breakthroughs lies in both embryonic and adult stem cell research (Bhikkhu, 2007).  However, 
almost anyone can agree that much more research is required before the actual applications for 
both embryonic and adult stem cell research can be determined, especially given several recent 
advances on alternative sources for embryo-derived ES cells (iPS cells, multipotent 
mesenchymal stem cells, and parthenotes). 
 
The Ethics of Parthenotes 
 Due to the controversial nature of ES cell research, and the potency limitations of adult 
stem cells, scientists have developed human parthenotes as an alternative.  Human parthenotes 
are created from eggs that are persuaded by chemical treatments to develop into an embryo in 
order to create ES cells (McConchie, 2005).    Although human parthenotes are not capable of 
progressing further into their development to allow for implantation in the uterus, parthenote ES 
cells are often referred to as embryonic-like, due to their ability to produce pluripotent cells 
(McConchie, 2005).   Some believe that parthenotes are a relatively moral source for ES cells 
compared to human embryos that are capable of implantation. 
 Although human parthenotes are not capable of developing into a fetus, there are still 
some ethical concerns to be addressed.  The main ethical dilemmas associated with parthenotes 
are the process still involves the ethics of donating eggs for medical research, and the debate as 
to the status of an embryo that cannot form an adult (McConchie, 2005).  Some people don‟t 
consider the parthenote to be a true embryo since it is unable to develop into a fetus, while others 
believe that they should be given the benefit of the doubt and treated as an embryo regardless of 
their developmental potential (McConchie, 2005).  In order for the moral status of the human 
parthenote can be determined, such ethical issues will remain. 
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The Ethics of iPS Cells 
 As discussed in Chapter-1, one of the hottest topics in all of stem cell research for the 
past two years has been the topic of induced pluripotent stem (iPS) cells.  The process as 
discovered in 2007 for human cells (Takahashi et al., 2007) involves isolating skin fibroblast 
cells from a patient, and transfecting them with four transcription factor genes to induce a de-
differentiated state to form pluripotent cells.  iPS cells are genetically identical to the patient 
(since they were obtained from the patient‟s own skin cells), so are less likely to be rejected by 
the patient during implant therapies.  The process has since been refined to using either two 
transcription factors, or even just polyarginine proteins, but the ethics remain the same, no 
embryo is used, yet the cells appear (so far) to have the same therapeutic potential as embryo 
derived ES cells.  Thus, much current research focuses on determining whether iPS cells truly 
are pluripotent, because if so, their use could obliterate the need for embryo-derived ES cells.   
 With respect to religious stances on iPS cells, due to their recent discovery no church has 
made a formal comment yet.  Although the iPS process creates stem cells genetically identical to 
a patient, it does not involve any therapeutic cloning from embryos to achieve this.  Because no 
embryos are involved, these cells should have the same moral status as adult stem cells, which 
even the conservative Catholic church is in favor of (Catholic Online, 2008; Pacholczyk, 2008). 
 
Religious Stances on Stem Cells 
The Christian Perspective 
 Most Christians believe that human life begins at the moment of conception, when an egg 
is fertilized by a sperm.  According to Christian tradition, the embryo is indeed a developing 
human person, regardless of the fact it is at the earliest stage of development (Jones, 2003).  
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Therefore, the embryo must be treated with respect regardless of its developmental stage 
(Bhikkhu, 2007).  Their rationale is supported by the Bible, which states that humans are made in 
the image of God, and therefore, every human being possesses the inherent right to life, dignity, 
and worth (Bhikkhu, 2007).  Therefore, Christianity teaches that the human embryo should be 
given the same moral status as any other developed human individual (Jones, 2003). 
 The Roman Catholic Church has been known for its rigid stance on ES stem cell 
research.  They view the destruction of the human embryo, created by any means, as a gravely 
illicit act which should be avoided at all costs (Correa and Sgreccia, 2000; Barry, 2007).  Pope 
Benedict has often stressed that the Catholic Church strongly opposes research which disrespects 
the human individual, including the embryo from the moment of conception (Catholic Online, 
2008).  The Pope also stated that the opposition of the Church to ES cell research “…is against 
those forms of research that involve the planned suppression of human beings who are already 
alive, though they may not have been born” (Catholic Online, 2008).  According to the Catholic 
Church, no matter how much mankind may benefit from ES cell research, the unethical means 
used to achieve those goals can never be justified (Catholic Online, 2008).   
 A majority of the Catholic Church‟s ethical concerns to ES cell research are addressed in 
their article, The Declaration on the Production and the Scientific and Therapeutic Use of Human 
Embryonic Stem Cells (Correa, 2000).  The first dilemma presented was “Is it morally licit to 
produce and/or use living human embryos for the preparation of ES cells?” (Correa, 2000).  The 
answer was negative, based on the belief that the living embryo is a human being from the 
moment of conception with a defined and unique identity (Correa, 2000).  The second ethical 
problem was “Is it morally licit to engage in so called therapeutic cloning?” (Correa, 2000).  
Therapeutic cloning involves the production of cloned human embryos followed by their 
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destruction to extract ES cells genetically identical to a patient.  According to the Catholic 
Church, the answer was negative, based on the belief that the destruction of the human embryo to 
obtain ES cells is immoral (Correa, 2000).  The third ethical issue presented was “Is it morally 
licit to use ES cells, and the differentiated cells obtained from them, which are supplied by other 
researchers or are commercially obtainable?” (Correa, 2000).  This was determined to be 
immoral because participation of any kind in ES cell research is gravely illicit (Correa, 2000).   
 Although the Catholic Church strongly rejects ES cell research, they do support research 
involving adult stem cells.  According to Father Tadeusz Pacholczyk, a neurologist and priest at 
the National Catholic Bioethics Center in Philadelphia, PA, the Catholic Church is supportive of 
adult and parthogenetic stem cell research (Barry, 2007; Catholic Online, 2008).  The Catholic 
Church is also supportive of research involving embryonic germ cells and umbilical cord stem 
cells, since neither involves the destruction of potential human life (Pacholczyk, 2008).  They 
argue that work being done with adult stem cells does not involve death for any individual 
involved since the stem cells are isolated from adult tissues, rather than embryonic (Catholic 
Online, 2008).  According to Pope Benedict, adult stem cell research maintains the respect due to 
every human individual at every stage of life (Catholic Online, 2008).  For this reason, the Pope 
has encouraged scientists to work together and increase research on adult stem cells in order to 
alleviate human anguish (Catholic Online, 2008). 
 A number of other Christian groups that are actually in favor of ES research.  Groups 
such as the Unitarian-Universalists, the Episcopal Church, the Evangelical Lutheran Church, the 
United Methodist Church, and the Church of Jesus Christ of Latter Day Saints, have no official 
position in the ES cell debate (Derbyshire, 2001).  Protestants have a wide range of perspectives 
regarding stem cell research.  Some Protestants, such as the Southern Baptist Convention, 
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believe that the embryo is the smallest and earliest form of life and thus should never be 
annihilated (Teaching About Religion, 2006).  Other Protestants, such as the American 
Presbyterian Church, believe that stem cell research would be ethical only if it was the only way 
to produce new medical therapies (Teaching About Religion, 2006).  Another Christian group, 
the Anglican-Episcopal tradition, believes the early embryo doesn‟t have the potential to become 
a human being until the fourteenth day, also known as the primitive streak.  The primitive steak 
is a moment in which the spinal cord begins to develop and the embryo can no longer divide into 
several embryos (Kohsl, 2008).  Thus the Episcopal church would allow research on 5-day old 
embryos.  Overall, most Protestants hold that ES cell research should be limited to up to 15 day 
old embryos left over from IVF clinics (not from paid donors) (Teaching About Religion, 2006).   
 
The Judaic Perspective 
 In general, the Jewish population supports stem cell research, particularly ES cell 
research, for several reasons.  During the first forty days of development, the human embryo is 
regarded as simply water (Dorff, 2000).  Since the embryo does not have the same form as a 
child does, it is not considered to be a human child (Dorff, 2000).  According to Judaism, the 
embryo does not become a human being until 41 days into gestation (Bhikkhu, 2007).  Once the 
embryo is 41 days old, it receives its soul and becomes a human individual.  However, the 
human embryo will not inherit personhood, a characteristic unique to developed human beings, 
until birth (Teaching About Religion, 2006).  Since the embryo is not considered to be a human 
being or a person until day 41, ES cell research based on the use of the 5-day old human embryo 
is not controversial (Bhikkhu, 2007).  Since the embryo is cultured in a petri dish, outside the 
human body, it has no potential to develop into a human person (Dorff, 2001).  Therefore, its 
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moral status is much less than that of an embryo developing in the womb during the first stages 
of embryonic development (Dorff, 2001).   
Jewish tradition also supports ES cell research since it has the possibility of producing 
new medical treatments with the potential to save many human lives (Bhikkhu, 2007).   In 1999, 
Rabbi Dorff sent a report to the White House, explaining that Jewish law endorses stem cell 
research since it could potentially cure numerous diseases, therefore promoting greater good 
(Derbyshire, 2001).  Jewish law supports the use of embryos left over from fertility clinics in 
scientific research since such embryos are not implanted in the uterine wall (Castillo, 2006).  For 
this reason, IVF embryos are not capable of developing into a human being, and therefore their 
use in science is justified.  They believe that the benefit of using embryos left over from fertility 
clinics or miscarriages is infinite, and that it would be immoral to not explore their potential to 
serve humanity (Bhikkhu, 2007).   
 According to Jewish tradition, disease can be overcome with the help of both natural and 
synthetic means (Dorff, 2000).  Physicians are considered to be God‟s helpers, since they are 
involved in healing mankind (Dorff, 2000).  Unlike many other religious populations, the Jewish 
community has no issue with the concept of “playing God” (Jakobovits, 2006).  This is 
permitted as long as we strive to heal and develop new medical treatments when possible 
(Jakobovits, 2006).  Since our bodies are made in the image of God, and thus belong to God, it is 
believed that humans have an obligation to God to produce and utilize new medical treatments 
that will allow us to better care for our bodies (Dorff, 2000).  Based on this line of thought, 
human beings have an obligation to God to develop new medical therapies and cures for 
debilitating disease to better preserve our bodies (Dorff, 2001).  According to Jewish law, 
medical therapies produced by natural or synthetic means are equally good and legitimate (Dorff, 
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2000).  Couples who no longer need the extra embryos created for IVF treatments should be 
highly encouraged to donate their embryos to scientific research (Dorff, 2001).   
Although Judaism supports the use of embryos created for fertility purposes in scientific 
research, creating human embryos for the sole purpose of this research is permitted only under 
one condition (Bhikkhu, 2007).  The best and most moral source for obtaining stem cells is from 
frozen embryos created for fertility purposes, since these embryos would normally be discarded 
when not used (Dorff, 2001).  However, embryos may also be created for medical and scientific 
research purposes only if the woman supplying the eggs donates only once or twice (Dorff, 
2001).  It is important to remember that human embryos, and even the egg and sperm which 
create them, should be respected for their potential for human life and procreation (Dorff, 2000).  
Although the destruction of the human embryo before the forty-first day is permitted by Jewish 
law, it is crucial to bear in mind that Jewish practice requires respect for such embryos, and 
consequently they should not be destroyed unnecessarily (Dorff, 2000).  
 
The Islamic Perspective 
 Islam teaches that although the embryo is alive once conceived, it is not a human being 
(Bhikkhu, 2007).  According to this perspective, the embryo does not become a human 
individual until it is about 4 months old, which is the moment when it receives its soul (Bhikkhu, 
2007).  Islamists believe that once an embryo is 121 days old (four months), “…an angel comes 
and blows the spirit into that individual” (Bhikkhu, 2007), and the behaviors and fate of the fetus 
is established.  Once this occurs, the fetus is considered to be a human being (Bhikkhu, 2007).   
 Islamists have made a vivid distinction between the early embryo and fetus, during the 
first 40 days it is an embryo, and after a fetus.  According to Islam, if a pregnant woman decides 
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to abort her baby during the early stages of gestation, then the woman‟s punishment would be 
less than if she had aborted a fetus later in her pregnancy (Kutty, 2007).  This infers that 
Islamists consider the early embryo to be of lesser value than the late stage fetus.  Since ES cells 
are cultivated from the destroyed early stage embryos, it is assumed that Islam permits ES cell 
research. 
 Thus, when it comes to stem cell research, Islam is generally in favor of it.  However, the 
ethical nature of the use of the embryo is also important (Bhikkhu, 2007).  If the ES cells are 
used to produce new tissues and organs for medical purposes, then the research is considered to 
be ethical and encouraged (Bhikkhu, 2007).  However, if ES cells are used to selectively 
generate offspring, then it is unethical and discouraged (Bhikkhu, 2007).  Also, the question of 
the production of human embryos solely to create stem cells is still highly debated in Islam 
(Castillo, 2006).  In general, Islamists believe that humans have an obligation to God to use 
wisdom to improve health (Frazzetto, 2004).  Since this is the case, stem cell research is 
considered to be “an act of faith in the ultimate will of God” (Frazzetto, 2004), as long as the 
objective is to improve human health. 
 
The Buddhist Perspective 
 Buddhism teaches that an embryo is alive and human from the moment of conception 
(Bhikkhu, 2007).  However, Buddhists believe that the human embryo does not have a mind or 
thought until it has been successfully implanted into the uterine wall (Castillo, 2006).  Since this 
is the case, the embryo is not considered to have attained personhood until birth (Hughes and 
Keown, 1995).  Buddhists believe that personhood is characterized by “the awareness of the 
difference between self and other”, and the ability to be conscious of the self and to take 
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thoughtful action (Hughes and Keown, 1995).  Furthermore, embryos that are contained in petri 
dishes do not possess thought or have a mind since they are not implanted, and therefore 
Buddhists may agree with ES cell research (Castillo, 2006).   
 Buddhism places great value on the notion of ahimsa, also known as non-harming 
(Keown, 2001).  Therefore, there are many stipulations associated with scientific research 
involving the destruction of the human embryo (Keown, 2001).  Actions which result in embryo 
harm go against the First Precept of Buddhism, which forbids causing injury or death to living 
individuals (Keown, 2001).  Buddhists believe first that any scientific research which requires 
the destruction of the human embryo is immoral (Keown, 2001).  Although ES cell research may 
be very controversial, Buddhists have no issue with adult stem cell research.   
 
The Hindu Perspective 
 Hinduism teaches that human life begins at conception, when the embryo is immediately 
given its soul (Castillo, 2006).  Since this is the case, Hindus believe that no person has the right 
to deliberately take life away from anyone, including the human embryo (Bhikkhu, 2007).  When 
it comes to stem cell research involving the destruction of the human embryo, no greater good 
can possibly be attained since the means are immoral (Bhikkhu, 2007).  Some even believe that 
severe consequences, rather than positive outcomes, will result from the production of medical 
treatments from human ES cell research (Bhikkhu, 2007).  Hindus argue that scientists should 
strive to determine the underlying source for disease, rather than masking symptoms with new 
treatments derived from ES cell research (Jyoti, 2007). 
 Relative to other religions around the world, Hinduism features a strong perspective 
regarding illness and disease.  Ancient medicine is still practiced today in the Hindu culture, 
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including Ayurvedic medicine.  Ayurvedic medicine is an ancient form of medicine that was 
created by Indian practitioners (Jyoti, 2007).  It is based on the concept that disease can be 
prevented through wisdom, since it encourages healthy lifestyles and certain spiritual practices 
(Jyoti, 2007).  Even though some practitioners may still become ill, it is believed that such illness 
can be successfully combated with the use of herbal medicine (Jyoti, 2007).  Hindus believe that 
ailments are mostly caused by previous actions, such as overindulging, drug and alcohol abuse, 
or other lifestyles which put stress on the body (Jyoti, 2007).  Such negative actions accumulate 
during each life and result in bad karma.  Bad karma is a personal fault, and Hindus believe that 
new medical treatments produced from ES cell research would make recovery from bad karma 
too convenient and easy, so should be avoided. 
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Chapter-4:  Stem Cell Legalities 
Kristin Newell 
 
 As is typical of any controversial new technology, laws have been enacted to control it.  
The purpose of this chapter is to discuss some of the U.S. and international laws that regulate 
embryo and stem cell usage, as an example of the impact of technology on society.   
 
Bush Administration Stem Cell Policy 
On August 9, 2001, former President Bush declared that all research scientists receiving 
federal funding for embryonic stem (ES) cell research could only work with ES cell lines created 
before August 9, 2001.  The White House claimed that there were over 60 usable ES cell lines 
already established, when in fact there were only about nine viable lines (Agnew, 2003).  A 
"line" of stem cells is a group of immortal cells derived from one particular embryo. Under the 
Bush Administration, it was illegal to create or destroy a human embryo in any experiment 
funded by the federal government. This included using any equipment paid for with federal 
funds, even if the experiment itself was being privately funded (in the latter case cloning and 
creating a human embryo is legal) (Dunn, 2005).  One year after President Bush placed 
restrictions on ES cell research, researchers were only able to access about four ES cell lines. 
The other ES cell lines were unavailable due to practical (non-viable cells) and legal 
complications. In addition, some cell lines were not real stem cells (Holden and Vogel, 2002).  
Thus, many scientists became concerned that the Bush ban on federal funding would severely 
restrict ES cell research in the U.S. 
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Due to the scientific outcry for more ES cell lines, congress drafted a bill to permit 
therapeutic cloning.  But in a 2003 State of the Union address, President Bush spoke in response 
to the Senate bill saying "no life should be started or ended as the object of an experiment" 
(Agnew, 2003).  On July 19, 2006, President Bush vetoed Congress' bid to end the governmental 
funding restrictions on human ES cell research funding in the United States.  President Bush 
vetoed the bill because he believed that it "would support the taking of innocent human life in the 
hope of finding medical benefits for others."  After President Bush's veto,  the House of 
Representatives' bid fell just shy of overriding the President's veto:  the bill passed in the House 
and Senate (235 to 193), but did not quite make the two thirds vote needed to override the 
President's veto (Babington, 2006).  In April 2007, U.S. senators voted for the second time to try 
to lift the restrictions on ES cell research, but the decision was again vetoed by President Bush 
(Wadman, 2007). 
During the Bush administration and its 2001 federal ban on deriving new ES cells, 
individual states and private foundations lead the way in stem cell research (Holden, 2006).  If 
states wanted any real progress to be made, they had to provide the legislation and funding to 
allow it (discussed below). 
 
Obama Administration Stem Cell Policy 
On March 9, 2009 President Obama lifted the 2001 restrictions on stem cells set in place 
by former President Bush (Holden, 2009).  This opened up federal grant money to be used to 
study the hundreds of stem cell lines created since August 9, 2001 when President Bush put in 
place the restrictions on ES cell research (Hayden, 2009).  When President Obama announced 
the ending of the restrictions on human ES cell research, he spoke of the promise of the research, 
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and believes it is our obligation as human beings to care for others and to ease those suffering if 
we have the ability to do so, and believes that this can be achieved through ES cell research. 
President Obama also hopes that America will be at the forefront of advances in ES cell research,  
will lead the world in the discoveries that come from it, and the research will lead to better 
understanding and possibly even treatment of many debilitating and even fatal diseases (Lee, 
2009). 
Obama‟s new laws regarding ES cell research make available the unused ES cell lines 
created by in vitro fertilization procedures after the Bush cutoff date, but still prohibits the use of 
cell lines created by therapeutic cloning with federal money (Holden and Kaiser, 2009).  In 
addition, egg donors are not to be paid, the embryos must come from discarded IVF embryos 
originally created for reproductive purposes.  And the new laws establish an NIH advisory panel 
to investigate new stem cell scientific findings to help formulate new guidelines. 
 
State Laws 
As mentioned above, in spite of the 2001 Bush ban on funding ES cell research, 
individual states can override the federal policy.  On September 23, 2002, Governor Gray Davis, 
of California signed a law allowing research on embryos, including those created by therapeutic 
cloning. The law also banned reproductive cloning (Garfinkle, 2004).  In 2004, California  
passed a bill (Proposition 71) allowing $3 billion to be spent over a span of ten years on stem cell 
research, including experiments working with cloned human embryos and the stem cells they 
produce  (Dunn, 2005). Some of the money from Proposition 71 went toward funding the 
creation of the California Institute of Regenerative Medicine (CIRM), which runs the state stem 
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cell research program. Of the 3 billion dollars for adult and ES cell research available through 
Proposition 71, only $350 million could be distributed each year (Johnson, 2005). 
On December 10, 2002, Stanford University (California) announced the establishment of 
its Institute for Cancer/Stem Cell Biology and Medicine, and joined the many U.S. universities 
that were trying to bypass the strict federal laws regarding stem cell research by creating 
privately funded institutions for undergoing stem cell research (Check, 2002). 
New Jersey followed California's lead and created the first state-funded stem cell research 
facility (Dunn, 2005). On January 2, 2004, Governor James E. McGreevey, of New Jersey, 
signed a law allowing research as well as the use of human ES cells, human adult stem cells from 
any source, and germ cells. The law also required infertility doctors to notify their patients about 
the option of donating human embryos following infertility treatment (Garfinkle, 2004).  In 
2005, New Jersey was the first state to actually use state funding for human ES cell research 
(Washington Post, 2005).  For 2005-2006 New Jersey allocated $23 million to go to the New 
Jersey Stem Cell Institute (Johnson, 2005). 
In March 2005, Massachusetts lawmakers approved legislation that allowed cloning for 
stem cell researchers, despite then Governor Mitt Romney's insistence on vetoing the bill (the 
bill passed by such a majority it could not be vetoed)  (Dunn, 2005).  Massachusetts legislators, 
after overriding the governor‟s veto, added two sections to the statute on stem cell research. The 
first section allowed for the creation of an institute for stem cell research as well as regenerative 
medicine along with $1,000,000 to be spent on the biology core. The second section allowed for 
the creation of a life sciences center promoting life sciences in applied and advanced sciences.  
These sciences to be studied include fields of life sciences such as regenerative medicine, stem 
cell research, nanotechnology, and biotechnology. The second section also created the Life 
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Sciences investment fund of $10,000,000 for allocations, appropriations, loans and grants for the 
investment or development in stem cell research or many other areas of the life sciences 
(Johnson, 2005). 
Many states created stem cell research centers to counteract the Bush administration‟s 
restrictions on ES cell research. In 2003, the Center for Stem Cells and Regenerative Medicine 
was created in Ohio, to support adult stem cell research, with $19.4 million in state funding.  In 
2006, Governor Blagojevich of Illinois signed an executive order designating the creation of the 
Illinois  Regenerative Medicine Institute (IRMI), and providing $10 million dollars (in April of 
2006) for grants to be awarded to medical research facilities undergoing research on adult and 
embryonic stem cells, and an additional $5 million dollars in August 2006 to be used in 2007. 
Indiana legislators appropriated $50,000 for the creation of the adult stem cell research facility at 
Indiana University.  The Maryland legislature created a $15 million fund for the creation of the 
Maryland Stem Cell Research Fund with the purpose of providing grants to fund adult and 
embryonic stem cell research (Johnson, 2005). In January of 2006, the New York state assembly 
approved legislation for the creation of the New York State Institute for Stem Cell Research and 
Regenerative Medicine as well as for allocating $300 million for regenerative medicine (which 
includes stem cell research) for the two years to follow (Washington Post, 2005).  
Many other states also passed legislation allocating money for stem cell research. 
Governor Jodi Rell, of Connecticut, in May of 2005, passed a bill providing $100 million over 
ten years for stem cell research (Washington Post, 2005). Washington created the Life Sciences 
Discovery Fund to provide money for stem cell research, but the source of the money had not yet 
been worked out at the establishment of the fund (Johnson, 2005).  In 2005, Governor Rod 
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Blagojevich, of Illinois, earmarked $10 million to be used for stem cell research (Washington 
Post, 2005).  
Not all states followed suit funding stem cell research.  Michigan state law bans 
therapeutic cloning, and therefore research on cloned embryos.  However, with written consent 
mothers are able to donate their fetuses, embryos, and newborn babies to scientific research 
(Washington Post, 2005).  As of 2005 the states in which no action has been taken either way 
regarding stem cells research are: Vermont, Delaware, Washington D.C.,  West Virginia, 
Kentucky, North Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Wisconsin, 
Missouri, Texas, Kansas, Colorado, Wyoming, Idaho, Nevada, Oregon, Washington, and Alaska  
(Washington Post, 2005). 
 
International Stem Cell Laws 
On July 20, 2006, Germany announced at the European Union (EU) meeting, " The 
European Union science program should not be used to give financial incentives to kill 
embryos," in response to the idea that some of the 51 billion euro would be dedicated to stem cell 
research for the years 2007-2013.  Within the EU, countries such as Germany, Poland, Austria, 
Lithuania, Slovenia, and Slovakia were opposed to the idea that some of the money to fund 
scientific research would be dedicated to researching something that is banded in some of the 
countries of the EU (Deutsche Welle, 2006). German law bans all research on human embryos, 
and only allows the creation of a human embryo for in vitro fertilization purposes.  Earlier in 
2002, however, Germany had passed a law allowing the import of human ES cells for use in 
research, but with close governmental control (Kim, 2002). 
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At the 2006 EU meeting, Finland, who held the rotating EU presidency, suggested that 
money be designated for ES cell research, but prohibiting the dispersal of funds for projects 
dealing with human genetic modification, human reproductive cloning, or the creation of human 
embryos for research (Deutsche Welle, 2006). 
Since 1990, the United Kingdom has allowed research to be done using embryos left over 
from assisted reproduction. In 2001, this law was reinterpreted and expanded beyond just 
reproductive biology, to include many other types of basic research.  United Kingdom law also 
allows the creation of embryos for the purpose of research. On August 11, 2004, a license was 
granted to the Newcastle Center for Life by the United Kingdom's Human Fertilisation and 
Embryology Authority, allowing the creation of colonies of human stem cells for the purpose of 
cloning, but not to clone a human. This license was good for a year and allowed researchers to 
continue to work on the ES cell lines they had created after the license had expired, but could not 
continue the isolation or cloning procedures following the expiration of the license (Garfinkle, 
2004). 
Sweden allows the use of unused in vitro fertilization embryos as a source of stem cells in 
research (Sweden's Stem Cell Success, 2002), as well as supporting the use of cloning human 
embryos for therapeutic purposes (Kim, 2002).  Therapeutic cloning of embryos for stem cell 
research, although currently a procedure not yet achieved in humans as of 2009, seemed to be a 
process which would be "ethically defensible" in Sweden (Sweden's Stem Cell Success, 2002).  
By 2002, Sweden had established a nationally funded stem cell bank, as well as the equivalent of 
almost 1 million U.S. dollars being disbursed by the Swedish National Research Council to fund 
the national stem cell bank for the three years (Sweden's Stem Cell Success, 2002).  The Michael 
J. Fox Foundation for Parkinson's Research, in March 2002, gave $4.4 million in U.S. dollars to 
 63 
Sweden for the creation of a stem cell line to be used purely for Parkinson's research.  Also, in 
March of 2002, Sweden and the U.S. announced a joint program to provide $7.5 million in U.S. 
dollars for stem cell research (Sweden's Stem Cell Success, 2002). 
 
On October 19, 2005 the World Stem Cell Foundation was unveiled in Seoul, South 
Korea, which intends to produce around 100 new ES cell lines each year. These stem cell lines 
are available to scientists around the world, but particularly in the U.S. where laws about federal 
funding under the Bush administration limited the research that can be done (Kaplan, 2005). 
Australia allows the use of embryos for research as long as they were created for the 
purpose of assisted reproduction before April 5, 2002.  Australia bans all type of human cloning, 
regardless of whether it is for research or reproduction. This ban includes embryo splitting, and 
everything that can be considered a form of cloning (Garfinkle, 2004). 
There are many countries that do not allow, or have strict regulations regarding 
embryonic stem cell research. The Swiss Constitution strictly prohibits the use of human 
embryos for research. It even goes so far as to say how many of a woman's eggs can be fertilized 
during assisted reproduction procedures (Garfinkle, 2004). French law prohibits research on 
human embryos (Kim, 2002).  Other countries with restrictive policies, ranging from outright 
banning of ES cell research to allowing research only on imported cell lines, to allowing research 
to be done on only a few already created stem cell lines, are Austria, Ireland, Germany, Italy, 
Poland, and Norway (Hoffman, 2005). 
Overall, countries with permissive stem cell policies, in which therapeutic cloning is 
allowed for use in human ES cell research, as well as the use of embryos created by in vitro 
fertilization procedures for embryonic stem cell research are: China, Australia, the United 
Kingdom, Belgium, India, Singapore, South Korea, Israel, Sweden, Japan and a few others 
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(Hoffman, 2005).   Countries with moderate policies, that allow the use of unused embryos 
created by in vitro fertilization clinics, but not those created by therapeutic cloning include: 
Canada, France, the United States, Brazil, Iran, Taiwan, The Netherlands, Spain, South Africa, as 
well as a few others (Hoffman, 2005).  And many countries still have no policies one way or 
another regarding human embryos or human embryonic stem cell research. Turkey is among 
these countries (Hoffman, 2005). 
With respect to induced pluripotent stem (iPS) cell technology, in June of 2008 Japan and 
the U.S. were competing to develop this technology, but the U.S. seemed to be having more 
success due to the commercialization of the Japanese developed technology (iPS) (Cyranoski, 
2008). 
 
Chapter-4 Conclusion 
California and South Korea appear to have the legislation that will lead to the most 
progress for ES cell research.  California and South Korea allow therapeutic cloning to create 
embryos for use in ES cell research. With the use of therapeutic cloning, ES cells can be created 
that have the exact same genes as a patient that could be receiving those cells to treat some 
debilitating or even fatal disease, which would result in no graft rejection and therefore should 
provide the best possible results. South Korea also has a good thing going for it in its creation 
and transportation of ES cell lines to other countries; it is this sharing of science and innovation 
that will lead to the most scientific progress and advances. People all over the world suffer from 
the many fatal and debilitating diseases, of which treatments are being pursued through stem cell 
research, especially with ES cells. 
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PROJECT CONCLUSIONS 
 
 
 
 The author of Chapters 1 and 3 believes that it is acceptable to work with ES cells due to 
their potential applications in medicine.  The potential for new medical treatments of currently 
incurable human diseases definitely outweighs the moral status of an IVF blastocyst.  As for the 
source of ES cells, they may be created from unused IVF embryos, originally created for 
reproductive purposes, or from paid egg donors.  However, it is acknowledged that some people 
believe ES cell research to be immoral.  In order to show respect for all varying opinions 
regarding ES cell research, iPS and adult stem cells should be used whenever possible as a 
substitute (as long as new medical therapies are being produced).  In regards to stem cell 
legalities, the author agrees most with Sweden‟s stem cell policies, since they allow the use of 
unused IVF embryos and support the cloning of human embryos. 
 The author of Chapters 2 and 4 believes that ES cells should be used in scientific research 
because they have great potential for use in regenerative medicine. The embryo is not yet a 
human being when ES cells are removed, rather, it is a mass of cells with the potential for 
personhood.  The author doesn‟t believe that destroying embryos is murder.  iPS and ASCs 
should be used in stem cell research whenever possible to learn more about various diseases and 
regenerative medicine.  The source of embryos used for ES cell research should come from 
many sources, the best being unused embryos from IVF clinics, which would be discarded 
anyway, and would not become a human being regardless of whether it is used for research. The 
country that has the best legislation regarding stem cell research is South Korea.  They have the 
least restrictions on stem cell research, which has the potential for treating many debilitating and 
fatal diseases that cause suffering in people worldwide. 
